These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 17988917)

  • 1. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.
    Zhang ZL; Zhu XJ; Wang X; Liang M; Sun J; Liu Y; Gao ZG; Wu JY; Dong XJ; Liu RK; Chen JT; Zhang YQ; Wang W; Zhang LP; Yin W
    Vaccine; 2012 Jun; 30(27):4028-33. PubMed ID: 22537990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules.
    López EL; Contrini MM; Xifró MC; Cattaneo MA; Zambrano B; Dumas R; Rouyrre N; Weber F
    Vaccine; 2007 Jan; 25(1):102-8. PubMed ID: 16914234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children].
    Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
    Zheng H; Chen Y; Wang F; Gong X; Wu Z; Miao N; Zhang X; Li H; Chen C; Hou X; Cui F; Wang H
    Vaccine; 2011 Nov; 29(48):9098-103. PubMed ID: 21875638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children.
    López EL; Contrini MM; Mistchenko A; Debbag R
    Pediatr Infect Dis J; 2010 Jun; 29(6):568-70. PubMed ID: 20195189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey.
    Soysal A; Gokçe I; Pehlivan T; Bakir M
    Eur J Pediatr; 2007 Jun; 166(6):533-9. PubMed ID: 17318620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The investigation on the safety and immunogenicity of inactived hepatitis A vaccine AVAXIM].
    Huang G; Wan Z; Li R
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Aug; 21(4):287-8. PubMed ID: 11860802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.
    Van Der Wielen M; Vertruyen A; Froesner G; Ibáñez R; Hunt M; Herzog C; Van Damme P
    Pediatr Infect Dis J; 2007 Aug; 26(8):705-10. PubMed ID: 17848882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
    Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
    Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.